Gain Therapeutics sees dossier submission for Phase 1 clinical trial of GT-02287 in GBA1 PD program by mid-2023.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GANX:
- Gain Therapeutics reports FY22 EPS ($1.48), consensus ($1.51)
- Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update
- Gain Therapeutics announces grant award by Eurostars with Innosuisse
- Gain Therapeutics Announces Grant Award by Eurostars with Innosuisse for Alpha-1 Antitrypsin Deficiency Research Program
- Gain Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference